Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quetiapine - AstraZeneca

Drug Profile

Quetiapine - AstraZeneca

Alternative Names: FK 949; FK949E; ICI 204636; Quetiapine extended release; Quetiapine fumarate; Quetiapine prolonged release; Seroquel; Seroquel XL; Seroquel XR

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Astellas Pharma; AstraZeneca; HUTCHMED; Luye Pharma Group
  • Class Analgesics; Antidepressants; Antipsychotics; Behavioural disorder therapies; Dibenzothiazepines; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Adrenergic uptake inhibitors; Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Bipolar disorders; Major depressive disorder; Manic episodes; Schizophrenia
  • Phase III Borderline personality disorders
  • Preregistration Submission Withdrawal Generalised anxiety disorder
  • No development reported Delirium; Irritable bowel syndrome
  • Discontinued Alcoholism; Behavioural disorders; Psychotic disorders

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 26 Sep 2022 Marketing and distribution rights for Quetiapine licensed to ICI Pakistan in Pakistan
  • 29 Jul 2022 US District Court for the District of Delaware dismisses claims against AstraZeneca for violating antitrust laws when settling patent litigation related to Seroquel XR
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top